Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 653-659

  Carlsson, Jörgen ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

EGFR; HER2; HER3; Her4; Imaging; Metastasis; Radionuclide; Receptors; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; DIAGNOSTIC AGENT; PROTEIN TYROSINE KINASE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DISSEMINATED CANCER; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; HUMAN; METABOLISM; NEOPLASM; REVIEW; SCINTISCANNING;

HUMANS; NEOPLASMS; RADIOISOTOPES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84863591835     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0307-x     Document Type: Article

References (52)

1. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3(3):349-70. Review.
2. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Berlin: Springer; 2008. p. 25-58. ISBN 978-1-4020-8695-3. Chapter 3.
3. McGill MA, McGlade CJ. Cellular signaling. In: Tannock IF, Hill RP, Bristow RC, Harrington L, editors. The basic science of oncology. New York: McGraw-Hill Medical Publishing Division; 2004. p. 142-66. ISBN-13:978-0-07- 138774-3, Chapter 8.
4. Pecorino L. Molecular biology of cancer. Mechanisms, targets and therapeutics. Oxford: Oxford University Press; 2005. ISBN 0-19-926472-4
5. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-57. Review.
6. Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther. 2011;11(49):937. Review.
7. Xu Y, Zhang Y, Ma S. EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 2011;73(3):249-55.
8. Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2011 Sep. 29. doi:10.1007/s10549-011-1781-y
9. Mukai H. Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol. 2010;15(4):335-40. Review.
10. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010;116(12):2856-67. Review.
11. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12(2):104-17. Review.
12. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505-16.
13. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2):124-34. Review.
14. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, et al. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res. 2009;15(11):3733-9.
15. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-54.
16. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268-72. Review.
17. Gusterson B, Cowley G, Smith JA, Ozanne B. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep. 1984;8:649-58.
18. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest. 1986;55:588-92.
19. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45:457-61.
20. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953-62.
21. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007;31:493-9.
22. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006;6:46.
23. Gullick WJ. The c-erbB3/HER3 receptor in human cancer. Cancer Surv. 1996;27:339-49.
24. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through metaanalysis. Breast Cancer Res Treat. 2011;129(3):659-74.
25. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer. 2004;90:2344-8.
26. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11(1):4-12.
27. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637-43.
28. Lo Russo PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437-47.
29. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004;6(3):R246-51.
30. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res. 2007;13(6):1926-35.
31. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU, et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007;67(1):326-31.
32. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2 positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule. Cancer Res. 2007;67(6):2773-82.
33. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res. 2003;9(3):1200-10.
34. Liu HL, Gandour-Edwards R, Lara Jr PN, de Vere White R, La Salle JM. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001;7(5):395-403.
35. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer. 2004;90(2):449-54.
36. Solit DB, Rosen N. Targeting HER2 in prostate cancer: where to next? J Clin Oncol. 2007;25(3):241-3.
37. Beaven AW, Goldberg RM. Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. Oncology (Williston Park). 2006;20(5):461-9. Review.
38. Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, et al. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep. 2011;25(1):3-11.
39. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002;440(2):187-94.
40. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002;38(8):1065-71.
41. Gardmark T, Wester K, De la Torre M, Carlsson J, Malmstrom PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 2005;95(7):982-6.
42. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 2002;41:282-8.
43. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int. 2005;95(9):1344-50.
44. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer. 2006;94:1703-9.
45. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c erbB-3. World J Surg. 1999;23:1010-8.
46. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:1323-7.
47. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol. 2008;15(4):1193-201.
48. Frejd YF. Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Berlin: Springer; 2008. p. 89-116. ISBN 978-1-4020-8695-3. Chapter 6.
49. Govindan SV, Goldenberg DM. New antibody conjugates in cancer therapy. Scientific World Journal. 2010;10:2070-89. Review.
50. Stigbrand T, Carlsson J, Adams GP. Developmental trends in targeted radionuclide therapy-biological aspects. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Berlin: Springer; 2008. p. 387-97. ISBN 978-1-4020-8695-3. Chapter 21.
51. Reilly RM. The radiochemistry of monoclonal antibodies and peptides. In: Rielly RM, editor. Monoclonal antibody and peptide-targeted radiotherapy of cancer. New York: Wiley; 2010. p. 39-100. ISBN 978-0-470-24372-5. Chapter 2.
52. Thomadsen B, Erwin W, Mourtada F. The physics and radiobiology of targeted radionuclide therapy. In: Speer TW, editor. targeted radionuclide therapy. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 71-87. ISBN 978-0-7817-9693-4. Chapter 6